GH Stock Up 15% after 7-Day Win Streak
Guardant Health (GH) stock hit day 7 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 15% return. The company has gained about $1.3 Bil in value over the last 7 days, with its current market capitalization at about $8.4 Bil. The stock remains 120.7% above its value at the end of 2024. This compares with year-to-date returns of 9.8% for the S&P 500.
GH provides liquid biopsy tests, data, and analytics for advanced and early-stage cancer detection, including precision oncology solutions for treatment selection and colorectal cancer screening. After this rally, is GH still a buy – or is it time to lock in gains? Deep dive with Buy or Sell GH.
Comparing GH Stock Returns With The S&P 500
The following table summarizes the return for GH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | GH | S&P 500 |
|---|---|---|
| 1D | 4.6% | -0.6% |
| 7D (Current Streak) | 15.2% | 1.0% |
| 1M (21D) | 64.5% | 1.9% |
| 3M (63D) | 66.0% | 9.3% |
| YTD 2025 | 120.7% | 9.8% |
| 2024 | 12.9% | 23.3% |
| 2023 | -0.6% | 24.2% |
| 2022 | -72.8% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has GH behaved after prior drops? See GH Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 66 S&P constituents with 3 days or more of consecutive gains and 34 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 39 | 15 |
| 4D | 22 | 3 |
| 5D | 0 | 16 |
| 6D | 3 | 0 |
| 7D or more | 2 | 0 |
| Total >=3 D | 66 | 34 |
Key Financials for Guardant Health (GH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $563.9 Mil | $739.0 Mil |
| Operating Income | $-564.7 Mil | $-443.6 Mil |
| Net Income | $-479.4 Mil | $-436.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $201.8 Mil | $203.5 Mil |
| Operating Income | $-126.0 Mil | $-111.0 Mil |
| Net Income | $-111.0 Mil | $-95.2 Mil |
While GH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.